lower estim morn follow diabet
relat newsflow past week sum what happen
 morgan healthcar confer pre-announc better result
guid street abbott receiv
approv januari sell libr medicar patient month earlier
expect libr began secur major commerci payor us start
januari announc last week resolv
pump avail guardian sensor manufactur issu
system sensor stock readi ship
get estim updat want cover
dexcom new patient growth number compani share us
follow healthcar confer driver behind revis
model today state met instal base target
end year patient y/e per ir split
us ou compar forecast us
patient patient ou us new patient growth non-medicar
popul patient expans coverag
medicar popul ad patient estim
us number gener in-lin medicar shortfal isnt
terribl surpris given rocki start program date
signific disconnect ou sale new patient
growth dexcom ou sale grew howev ou new
patient growth far assumpt use street
big spread dexcom ou revenu growth new patient
growth reflect benefit higher sell price buy distributor
shift sale mix distributor direct better reimburs
increas util patient gain access reimburs particularli
germani factor increas asp uptick util
appar magnitud far greater expect account
major ou revenu growth know weve lower
new patient growth forecast lower ou sale estim
detail
page analyst certif import disclosur
 morgan seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report singl
factor make invest decis
forecast sale
compar manag guidanc assum us sale
ou sale vs prior assumpt
us ou us forecast commerci sale
medicar sale vs assum add new
commerci patient new medicar patient updat
forecast account fact guardian sensor suppli
issu resolv month ahead expect set stage
guardian stand-alone perhap later year libr secur medicar approv
januari month sooner expect moder ou forecast call
new patient modest gain sensor util vs
uplift recogn vs
confer manag guid stronger growth vs
back launch that way see expect
best quarter year worst model growth
work medicar backlog libr competit
hasnt fulli kick yet growth patient hold back anticip
launch forecast growth launch still assum juli
launch model competit tougher comp lower
price begin greater impact note assum cut hardwar price
launch weve state believ get approv ahead
expect manag suggest confer wouldnt
surpris see late approv import view modest
impact cadenc quarter quarter growth
come outlook get much challeng tough
comp anniversari medicar launch start catch compani
impact increas competit ramp forecast
sale vs street us sale
ou sale assum hardwar sale declin lower
transmitter/receiv price sensor sale grow forecast new
patient growth us commerci popul medicar
outsid us forecast growth us commerci new patient growth
tailwind launch also face increas competit pressur libr
broader reimburs pediatr label also assum
verili product approv contribut non-intens
follow news flow key issu see
still impact increas competit new patient growth us commerci
popul abbott progress secur commerci reimburs libr
announc first pace uptak
medicar popul reimburs market develop progress
europ price strategi launch medtron
aggress go dexcom/anima instal base resolv
capac issu
invest thesi valuat risk
last five year stori predominantli focus two item
increas accuraci compani cgm technolog increas util
improv accuraci marri increas access give patient
caregiv abil continu track blood glucos level receiv alarm
alert smart phone yet two new element alter dexcom
stori realiti hadnt first obviou competit
second less decreas abil reli pump partner
posit segment market year believ variou non-
pump compani need need one
individu elect exit market tandem seemingli financi
life support competit posit pump popul weaken
led compani come low end growth guidanc despit
effect one-year delay medtron launch better-than-expect
look forward stori hing entranc abbott us
cgm market foray stand-alone cgm busi disrupt
cgm market outlook long-term econom cgm
market abbott launch first gener product us offer
substanti incent patient new exist cgm user trial libr
commerci payor yet board point everyth self-pay
though chang abbott medicar reimburs libr
cours expect announc number agreement privat insur
pt valu ev/sal ev/sal
modest discount high growth med-tech name view reason
given compani top-lin growth outlook end decad
size potenti market opportun type patient insulin intens type ii
off-set uncertainti new competit
risk rate price
risk upsid rate price target includ impact competit
us could less expect sale newli launch
medicar cgm could perform better expect product approv could come
faster expect
risk downsid rate price target includ market adopt could
track current expect competit launch could
detriment market posit pipelin could
neg impact fda delay clinic failur
summari financi
cash equival
flow oper activ
o/w chang work capit
flow invest activ
sale
flow financ activ
net chang cash
adj free cash flow firm
compani report morgan estim
note million except per-shar data fiscal year end dec o/w
analyst certif research analyst denot ac cover report certifi multipl research
analyst primarili respons report research analyst denot ac cover within document
individu certifi respect secur issuer research analyst cover research view
express report accur reflect person view subject secur issuer part
research analyst compens directli indirectli relat specif recommend view
express research analyst report korea-bas research analyst list front cover also certifi per
kofia requir analysi made good faith view reflect opinion without undu influenc
